Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2014

Open Access 01-09-2014 | Original Article – Clinical Oncology

IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia

Authors: Tomasz Wróbel, Katarzyna Gębura, Barbara Wysoczańska, Bożena Jaźwiec, Olga Dobrzyńska, Grzegorz Mazur, Kazimierz Kuliczkowski, Katarzyna Bogunia-Kubik

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2014

Login to get access

Abstract

Purpose

Recent studies have suggested that Th17 cells may play a role in the pathogenesis of acute myeloid leukemia (AML). This subset of CD4+ cells is characterized by interleukin (IL)-17A and IL-17F production, which share strong homology, and surface expression of the IL-23 receptor (IL-23R). The present study aimed to determine the association between the polymorphic features located within the IL-17A, IL-17F and IL-23R genes and disease susceptibility, progression and response to therapy. In addition, the relationship between the polymorphic variants and the plasma IL-17 levels in patients was analyzed.

Methods

For this purpose, 187 individuals of Polish origin including 62 AML patients and 125 healthy controls were typed for IL-17A (rs2275913; G-197A), IL-17F (rs763780; A7488G; His161Arg) and IL-23R (rs11209026, G1142A; Arg381Gln) alleles.

Results

The rs763780 IL-17F polymorphism appeared to be associated with susceptibility to the disease. The presence of the minor (G) variant (RR = 4.76, p < 0.001) and its homozygosity (RR = 23.02, p < 0.005) was more frequent among patients than healthy individuals. No significant association was observed for either other polymorphisms studied or IL-17 levels.

Conclusions

Thus, the rs763780 IL-17F polymorphism was found to be associated with predisposition to AML in the Polish population.
Literature
go back to reference Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914PubMedCrossRef Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914PubMedCrossRef
go back to reference Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051–1057PubMedCrossRef Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051–1057PubMedCrossRef
go back to reference Espinoza JL, Takami A, Nakata K et al (2011) A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS ONE 6:e26229PubMedCentralPubMedCrossRef Espinoza JL, Takami A, Nakata K et al (2011) A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS ONE 6:e26229PubMedCentralPubMedCrossRef
go back to reference Hot A, Zrioual S, Toh M, Lenief V, Miossec P (2011) IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 70:341–348PubMedCrossRef Hot A, Zrioual S, Toh M, Lenief V, Miossec P (2011) IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 70:341–348PubMedCrossRef
go back to reference Kawaguchi M, Takahashi D, Hizawa N et al (2006) IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 117:795–801PubMedCrossRef Kawaguchi M, Takahashi D, Hizawa N et al (2006) IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 117:795–801PubMedCrossRef
go back to reference Li P, Ji M, Park J, Bunting KD, Ji C, Tse W (2012) Th17 related cytokines in acute myeloid leukemia. Front Biosci (Landmark Ed) 17:2284–2294CrossRef Li P, Ji M, Park J, Bunting KD, Ji C, Tse W (2012) Th17 related cytokines in acute myeloid leukemia. Front Biosci (Landmark Ed) 17:2284–2294CrossRef
go back to reference McKenzie BS, Kastelein RA, Cua DJ (2006) Understanding the IL-23-IL-17 immune pathway. Trends Immunol 7:17–23CrossRef McKenzie BS, Kastelein RA, Cua DJ (2006) Understanding the IL-23-IL-17 immune pathway. Trends Immunol 7:17–23CrossRef
go back to reference Nurieva R, Yang XO, Martinez G et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480–483PubMedCrossRef Nurieva R, Yang XO, Martinez G et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480–483PubMedCrossRef
go back to reference Tian T, Sun Y, Li M et al (2013) Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia. Clin Chim Acta 426C:108–113CrossRef Tian T, Sun Y, Li M et al (2013) Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia. Clin Chim Acta 426C:108–113CrossRef
go back to reference Wrobel T, Mazur G, Jazwiec B, Kuliczkowski K (2003) Interleukin-17 in acute myeloid leukemia. J Cell Mol Med 7:472–474PubMed Wrobel T, Mazur G, Jazwiec B, Kuliczkowski K (2003) Interleukin-17 in acute myeloid leukemia. J Cell Mol Med 7:472–474PubMed
go back to reference Wu C, Wang S, Wang F et al (2009) Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 158:199–204PubMedCentralPubMedCrossRef Wu C, Wang S, Wang F et al (2009) Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 158:199–204PubMedCentralPubMedCrossRef
Metadata
Title
IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia
Authors
Tomasz Wróbel
Katarzyna Gębura
Barbara Wysoczańska
Bożena Jaźwiec
Olga Dobrzyńska
Grzegorz Mazur
Kazimierz Kuliczkowski
Katarzyna Bogunia-Kubik
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1674-7

Other articles of this Issue 9/2014

Journal of Cancer Research and Clinical Oncology 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.